Skip to main content
VITRAFY LIFE SCIENCES LIMITED logo

VITRAFY LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · VFY ISIN · AU0000361297 ASX Professional, scientific and technical activities
Open in API
Filings indexed 93 across all filing types
Latest filing 2026-06-03 Investor Presentation
Country AU Australia
Listing ASX VFY

About VITRAFY LIFE SCIENCES LIMITED

https://www.vitrafy.com

Vitrafy Life Sciences Limited specializes in the development and commercialization of advanced cryopreservation technologies designed to optimize the preservation and transport of biological materials. The company provides end-to-end cold chain solutions, focusing on maintaining the viability and functionality of sensitive life science products, including cells, tissues, and organs. Its core technology utilizes precise, automated cooling and warming protocols to minimize cellular damage during the freezing process, addressing critical challenges in regenerative medicine, cell and gene therapy, and biobanking. By integrating hardware, software, and specialized consumables, Vitrafy aims to standardize cryopreservation workflows and improve clinical outcomes through enhanced sample recovery and data-driven monitoring throughout the supply chain.

Recent filings

Filing Released Lang Actions
Vitrafy Investor Presentation 27 pages 1.4MB
Investor Presentation Classification · 90% confidence The document is structured as a multi-page slide deck with an ASX ticker, disclaimers, company highlights, market overview, technology positioning, and forward‐looking statements. It lacks actual financial statements or regulatory filing language and instead focuses on strategy, product, and market positioning typical of an investor pitch. Therefore, it is an Investor Presentation.
2026-06-03 English
Vitrafy enters a partnership with Vitalant Innovation Center 3 pages 251.0KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement of a commercial partnership between Vitrafy and Vitalant Innovation Center. It does not present financial results, management changes, capital raising, M&A, or other specialized filings. It is a general corporate announcement falling into the regulatory announcement fallback category.
2026-06-02 English
Final US Army Phase 2 Platelet Results 5 pages 464.9KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement presenting scientific trial results (Phase II platelet cryopreservation study) with no financial statements or regulatory form structure, not an investor slide deck or earnings release. It is a general regulatory filing/announcement (fallback category) on the ASX, so it should be classified as a Regulatory Filings announcement (RNS).
2026-05-21 English
Phase 2 USAISR Platelet Results Investor Presentation 7 pages 412.1KB
Investor Presentation Classification · 95% confidence The document is a detailed slide deck (“presentation”) dated 22 May 2026 by Vitrafy Life Sciences Limited (ASX: VFY), containing scientific study results, key highlights, background, and outlook sections typical of an investor-facing pitch rather than a formal regulatory filing or earnings announcement. It does not include standalone financial statements or Q&A transcript, nor an officer’s certification or simple publication notice. It is therefore classified as an Investor Presentation (Code: IP).
2026-05-21 English
Phase 2 USAISR Platelet Results Investor Briefing 1
Regulatory Filings Classification · 50% confidence The document is an ASX announcement inviting investors to a Phase II results webinar. It does not include any financial statements, transcripts, slides, or report attachments, nor does it announce management changes, capital actions, dividends, or legal matters. It is simply a regulatory disclosure of an upcoming investor briefing, which does not fit any specific category (e.g., Investor Presentation would require the actual slides/presentation). Therefore, it falls under the fallback category for general regulatory announcements.
2026-05-21 English
Q3 FY26 Quarterly Activities Report and Appendix 4C 13 pages 865.7KB
Interim / Quarterly Report Classification · 92% confidence The document is titled “ASX ANNOUNCEMENT 28 April 2026: Vitrafy Life Sciences Quarterly Activities Report & Appendix 4C – Quarter 3, Financial Year 2026.” It includes detailed operational highlights and a full Appendix 4C cash flow statement with actual cash flow line items and commentary under ASX Listing Rule 4.7B. This is not merely an earnings release or presentation but a comprehensive quarterly activities and financial report for a period shorter than a full fiscal year, satisfying the Interim/Quarterly Report definition. Q3 2026
2026-04-27 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.